The event with the title “New developments in In Vitro Fertilisation” was completed successfully in our Unit on 27th November 2014.The director of our Unit, Dr Trifon Lainas, met with new and old colleagues and informed them for the participation of Eugonia in these developments by:

• our presence in Greek and international conferences through announcements or oral presentations
• the publication of original studies in approved international magazines
• the application of new methods that result in high success rates

Image 1: Event 2014

Image 2:  Event 2014

Image 3:  Event 2014

Image 4:  Event 2014

The scientific team of Eugonia actively participated in 3 big international conferences within 2014, with 4 original studies of high impact.They are some of the largest and most important conferences worldwide in Reproductive Medicine  and Endoscopy, during which the latest achievements of the international scientific community are presented.Munich, July 2014: Oral presentation at the ESHRE (European Society of Human Reproduction and Embryology) Annual Meeting.

• A new single medium for embryo culture is associated with improved blastocyst development and quality.

• Higher implantation and pregnancy rates, and fewer miscarriages in women without hysteroscopic findings, suggesting that hysteroscopy prior to IVF treatment may improve pregnancy rates.

• The levels of endogenous progesterone are related with subsequent pregnancy rates following IVF treatment. These are 2 large studies with more than 3000 patients, based on Eugonia’s extensive and detailed database, which can only be compared to databases of large international centers.

A novel research study of Eugonia was accepted for oral presentation at the recent annual meeting of the European Society of Human Reproduction and Embryology (ESHRE), that took place at Munich on 29 June-2 July 2014. Our study involves the improvement of embryo culture conditions.This is the largest annual conference worldwide in the field of IVF, which presents the most recent advances of the international scientific community. The acceptance letter from ESHRE clearly states that all submitted studies are assessed anonymously by 4 international reviewers, in order to identify the best ones. As a result, only studies of high impact and originality are accepted.Ιt is an official recognition of our team’s research activity, in our continuous effort to increase pregnancy rates.This is the third year that Eugonia actively participates in the ESHRE Annual Meeting with an oral presentation.

The scientific team of Eugonia has described the only available treatment worldwide for the treatment of severe OHSS using GnRH antagonist administration.In our new study, we provide an explanation on the mode of action of the antagonist, based on the pathophysiology of OHSS.Our data show that GnRH antagonist causes a rapid decline of VEGF, the primary angiogenic factor responsible for the development of OHSS.It must be noted that OHSS is the most serious complication of IVF programs. Until recently, there was no established cure for severe OHSS, which often requires patient hospitalization.Our study was published in the official journal of the Royal College of Obstetrics and Gynaecology, UK (BJOG: An international Journal of Obstetrics and Gynaecology). 

Successful organising of a day long seminar by Eugonia titled: "Advances in Assisted Reproduction", 19th February 2010.

Eugonia organised a day long seminar titled "Advances in Assisted Reproduction" at the Athens Hilton Hotel on the 19th of February 2010, with presentations from the doctors and embryologists of Eugonia in the following subjects:

"Ovarian Stimulation protocols. Agonists or Antagonists?" Dr Trifon G. Lainas

"Advances in Embryology" George Iliadis

"Unbiased Unit Selection: Do pregnancy rates and scientific publications count?" Dr Ioannis Sfontouris

"Collaboration of the referring gynaecologist with the Assisted Reproduction Units" Dr George Petsas

Accreditation of Eugonia with ISO 9001 from EKEVIL (Official ISO Accreditation Governmental Body in Greece)

In January 2010, Eugonia was officially accredited with ISO 9001:2008 for services in Assisted Reproduction following an inspection of our Quality Management System from the official ISO accreditation governmental body in Greece (ΕΚΕΒΥΛ).

Dr Trifon Lainas and Dr Ioannis Sfontouris participated at the Fertility Summit "Advancing the Science with a patient-focused vision", which took place in Dublin, on 2-3 December 2011. The conference was attended by a limited number of distinguished specialists with world-wide recognition in the field of Assisted Reproduction. New clinical and embryological developments in IVF were presented, and new principles for the treatment of complications like ovarian hyperstimulation syndrome (OHSS) were extensively discussed.

Once more, we found ourselves in the centre of developments based on our already published research, and we actively contributed in the establishment of strategies that will affect the future of OHSS prevention and treatment.

Eugonia was represented by Dr Trifon Lainas, Director of the unit, Dr George Lainas and Dr Ioannis Sfontouris, Clinical Embryologist, in a scientific summit that took place in Barcelona from the 11th to the 13th of March 2010.

During the conference, new assisted reproduction methods were discussed under the coordination of world renowned scientists and the presentation of the scientific and research work of Eugonia led to international acceptance and recognition.

Eugonia was represented by Dr Trifon Lainas, Director of the unit, Dr Ioannis Zorzovilis, Dr George Lainas, Dr Ioannis Sfontouris, Clinical Embryologist and Mrs Georgia Stavropoulou, Head Nurse of the unit, in the Annual Conference of the European Society of Human Reproduction and Embryology that took place in Rome from the 27th to the 30th of July 2010.

Pioneering new method for the management of the established severe ovarian hyperstimulation syndrome (OHSS) – World's first births from Eugonia's team.

With a pioneer new therapeutic system for the management of the already established severe ovarian hyperstimulation syndrome (OHSS) with the administration of GnRH antagonist, we managed to successfully and safely reverse the development of the syndrome to that of an outpatients' level by avoiding hospital admission (Lainas et al., 2009b; Lainas et al, 2007).

Furthermore, we achieved the world's first births following blastocyst transfer in an already established severe OHSS (Lainas et al., 2009a).